Skip to main content

Sichuan Kelun-Biotech Biopharmaceutical

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a Chinese biopharmaceutical company engaged in the discovery, development, and commercialization of novel oncology therapies. The company specializes in antibody-drug conjugates, monoclonal antibodies, and targeted small molecule therapies for advanced solid tumors and hematological malignancies. Its core pipeline features sacituzumab tirumotecan and multiple clinical-stage antibody-drug conjugate candidates designed to target specific cancer cell antigens. Principal revenue is derived from milestone payments, upfront licensing fees from international biopharmaceutical partnerships, research collaborations, and commercial sales of approved oncology products in China. Kelun-Biotech is recognized as a global innovator in antibody-drug conjugate technology, holding strategic licensing partnerships with major pharmaceutical corporations like Merck & Co. Headquartered in Chengdu, China, the company's common shares are publicly traded on the Hong Kong Stock Exchange under the ticker 6990.

15 of the funds FundTelligence covers report a position in Sichuan Kelun-Biotech Biopharmaceutical.

Legal name
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
Sector
Health Care
Country
China
Funds holding it
15

Funds holding Sichuan Kelun-Biotech Biopharmaceutical

Showing the 8 largest of 15 funds holding it.

Loading...